(CVRX) CVRx - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 237m USD | Total Return: -21.9% in 12m

Stock Medical Devices, Neuromodulation, Cardiovascular
Total Rating 33
Safety 30
Buy Signal -0.91
Medical Devices -5.6
Health Care Equipment -4.4
Market Cap: 237m
Avg Trading Vol: 1.68M USD
ATR: 7.38%
Peers RS (IBD): 73.0
Risk 5d forecast
Volatility92.4%
Rel. Tail Risk-21.8%
Reward TTM
Sharpe Ratio0.16
Alpha-51.73
Character TTM
Beta1.384
Beta Downside2.473
Drawdowns 3y
Max DD85.64%
CAGR/Max DD0.00
EPS (Earnings per Share) EPS (Earnings per Share) of CVRX over the last years for every Quarter: "2021-03": -0.7, "2021-06": -48.48, "2021-09": -0.3, "2021-12": -0.52, "2022-03": -0.49, "2022-06": -0.54, "2022-09": -0.48, "2022-12": -0.51, "2023-03": -0.55, "2023-06": -0.56, "2023-09": -0.43, "2023-12": -0.44, "2024-03": -1.04, "2024-06": -0.65, "2024-09": -0.57, "2024-12": -0.43, "2025-03": -0.53, "2025-06": -0.57, "2025-09": -0.49, "2025-12": -0.46, "2026-03": 0,
EPS CAGR: 19.95%
EPS Trend: 32.7%
Last SUE: 2.93
Qual. Beats: 1
Revenue Revenue of CVRX over the last years for every Quarter: 2021-03: 2.86, 2021-06: 3.123, 2021-09: 3.395, 2021-12: 3.658, 2022-03: 4.076, 2022-06: 5.031, 2022-09: 6.186, 2022-12: 7.176, 2023-03: 7.979, 2023-06: 9.5, 2023-09: 10.511, 2023-12: 11.305, 2024-03: 10.77, 2024-06: 11.807, 2024-09: 13.373, 2024-12: 15.342, 2025-03: 12.348, 2025-06: 13.589, 2025-09: 14.69, 2025-12: 16.024, 2026-03: null,
Rev. CAGR: 44.06%
Rev. Trend: 91.0%
Last SUE: 0.77
Qual. Beats: 0
Risks
Technicals: volatile
Description: CVRX CVRx

CVRx, Inc. is a Minneapolis-based medical device company specializing in neuromodulation therapies for cardiovascular disease. Its primary product, the Barostim system, is an implantable technology designed to stimulate carotid artery baroreceptors to regulate the autonomic nervous system. The company operates a commercial-stage business model, utilizing a combination of direct sales forces and independent distributors to reach markets in the United States and Europe.

The cardiovascular neuromodulation sector focuses on treating chronic conditions by modulating nerve activity rather than relying solely on pharmacological interventions. As a Health Care Equipment provider, CVRx manages the complex regulatory pathways and clinical trial requirements necessary to maintain market authorization for Class III medical devices. For a deeper look into the companys valuation metrics and market position, consider reviewing the data on ValueRay. The firm’s integration into the autonomic nervous system market positions it within a specialized niche of the broader medical technology landscape.

Headlines to Watch Out For
  • Barostim adoption drives revenue growth
  • Reimbursement policies impact device sales
  • Clinical trial results influence market expansion
  • Regulatory approvals critical for new indications
  • Competition from alternative therapies affects market share
Piotroski VR‑10 (Strict) 1.5
Net Income: -53.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.39 > 0.02 and ΔFCF/TA -8.53 > 1.0
NWC/Revenue: 155.9% < 20% (prev 232.1%; Δ -76.18% < -1%)
CFO/TA -0.38 > 3% & CFO -40.2m > Net Income -53.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.63 > 1.5 & < 3
Outstanding Shares: last quarter (26.2m) vs 12m ago 16.03% < -2%
Gross Margin: 85.33% > 18% (prev 0.84%; Δ 8.45k% > 0.5%)
Asset Turnover: 47.56% > 50% (prev 38.45%; Δ 9.12% > 0%)
Interest Coverage Ratio: -6.35 > 6 (EBITDA TTM -47.6m / Interest Expense TTM 5.83m)
Altman Z'' -15.00
A: 0.84 (Total Current Assets 101.6m - Total Current Liabilities 13.3m) / Total Assets 104.8m
B: -5.64 (Retained Earnings -590.7m / Total Assets 104.8m)
C: -0.31 (EBIT TTM -37.0m / Avg Total Assets 119.1m)
D: -9.02 (Book Value of Equity -590.6m / Total Liabilities 65.5m)
Altman-Z'' Score: -24.40 = D
Beneish M -2.93
DSRI: 1.04 (Receivables 10.7m/9.27m, Revenue 56.7m/51.3m)
GMI: 0.98 (GM 85.33% / 83.75%)
AQI: 1.23 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 1.10 (Revenue 56.7m / 51.3m)
TATA: -0.13 (NI -53.3m - CFO -40.2m) / TA 104.8m)
Beneish M-Score: -2.93 (Cap -4..+1) = A
What is the price of CVRX shares? As of April 06, 2026, the stock is trading at USD 9.01 with a total of 135,402 shares traded.
Over the past week, the price has changed by +1.69%, over one month by +7.65%, over three months by +17.47% and over the past year by -21.92%.
Is CVRX a buy, sell or hold? CVRx has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy CVRX.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CVRX price?
Wallstreet Target Price 11.2 24%
Analysts Target Price 11.2 24%
CVRX Fundamental Data Overview as of 06 April 2026
P/S = 4.1847
P/B = 6.0286
Revenue TTM = 56.7m USD
EBIT TTM = -37.0m USD
EBITDA TTM = -47.6m USD
Long Term Debt = 49.5m USD (from longTermDebt, last quarter)
Short Term Debt = 342k USD (from shortTermDebt, two quarters ago)
Debt = 50.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -24.9m USD (from netDebt column, last quarter)
Enterprise Value = 212.1m USD (237.1m + Debt 50.8m - CCE 75.7m)
Interest Coverage Ratio = -6.35 (Ebit TTM -37.0m / Interest Expense TTM 5.83m)
EV/FCF = -5.21x (Enterprise Value 212.1m / FCF TTM -40.8m)
FCF Yield = -19.21% (FCF TTM -40.8m / Enterprise Value 212.1m)
FCF Margin = -71.93% (FCF TTM -40.8m / Revenue TTM 56.7m)
Net Margin = -94.10% (Net Income TTM -53.3m / Revenue TTM 56.7m)
Gross Margin = 85.33% ((Revenue TTM 56.7m - Cost of Revenue TTM 8.31m) / Revenue TTM)
Gross Margin QoQ = 86.28% (prev 86.81%)
Tobins Q-Ratio = 2.02 (Enterprise Value 212.1m / Total Assets 104.8m)
Interest Expense / Debt = 2.79% (Interest Expense 1.42m / Debt 50.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -29.2m (EBIT -37.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.63 (Total Current Assets 101.6m / Total Current Liabilities 13.3m)
Debt / Equity = 1.29 (Debt 50.8m / totalStockholderEquity, last quarter 39.3m)
 Debt / EBITDA = 0.52 (negative EBITDA) (Net Debt -24.9m / EBITDA -47.6m)
 Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -24.9m / FCF TTM -40.8m)
 Total Stockholder Equity = 53.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.76% (Net Income -53.3m / Total Assets 104.8m)
RoE = -99.33% (Net Income TTM -53.3m / Total Stockholder Equity 53.7m)
RoCE = -35.83% (EBIT -37.0m / Capital Employed (Equity 53.7m + L.T.Debt 49.5m))
 RoIC = -28.33% (negative operating profit) (NOPAT -29.2m / Invested Capital 103.1m)
 WACC = 9.32% (E(237.1m)/V(287.9m) * Re(10.85%) + D(50.8m)/V(287.9m) * Rd(2.79%) * (1-Tc(0.21)))
Discount Rate = 10.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.20%
 [DCF] Fair Price = unknown (Cash Flow -40.8m)
 EPS Correlation: 32.70 | EPS CAGR: 19.95% | SUE: 2.93 | # QB: 1
Revenue Correlation: 91.03 | Revenue CAGR: 44.06% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.52 | Chg7d=+0.000 | Chg30d=+0.005 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-12-31): EPS=-2.01 | Chg7d=+0.000 | Chg30d=+0.021 | Revisions Net=-3 | Growth EPS=+1.6% | Growth Revenue=+14.4%
EPS next Year (2027-12-31): EPS=-1.78 | Chg7d=+0.000 | Chg30d=-0.047 | Revisions Net=-4 | Growth EPS=+11.5% | Growth Revenue=+18.3%
[Analyst] Revisions Ratio: -0.20 (2 Up / 3 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle